Page 71 - MEMORIA ANUAL 2021

MEMORIA ANUAL 2021 SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
PETHEMA
FUNDACIÓN ESPAÑOLA DE HEMATOLOGÍA Y HEMOTERAPIA
Acha P, Palomo L, Fuster-Tormo F, Xicoy B, Mallo M, Manzanares A, Grau J, Marcé S, Gra- nada I, Rodríguez-Luaces M, Diez-Campelo M, Zamora L, Solé F .
Grupo cooperativo coautor: GESMD .
• Outcomes of patients with chronic myelomonocytic leukaemia treated with non-cu- rative therapies: a retrospective cohort study.
Lancet Haematol. 2021 Feb;8(2):e135-e148. doi: 10.1016/S2352-3026(20)30374-4. Pleyer L, Leisch M, Kourakli A, Padrón E, Maciejewski JP, Xicoy Cirici B, Kaivers J, Un- gerstedt J, Heibl S, Patiou P, Hunter AM, Mora E, Geissler K, Dimou M, Jiménez Lorenzo MJ, Melchardt T, Egle A, Viniou AN, Patel BJ, Arnán M, Valent P, Roubakis C, Bernal Del Castillo T, Galanopoulos A, Calabuig Muñoz M, Bonadies N, Medina de Almeida A, Cer- mak J, Jerez A, Montoro MJ, Cortés A, Avendaño Pita A, López Andrade B, Hellstroem- Lindberg E, Germing U, Sekeres MA, List AF, Symeonidis A, Sanz GF, Larcher-Senn J, Greil R .
Grupo cooperativo coautor: GESMD .
• Different methylation signatures at diagnosis in patients with high-risk myelodys- plastic syndromes and secondary acute myeloid leukemia predict azacitidine re- sponse and longer survival.
Clin Epigenetics. 2021 Jan 14;13(1):9. doi: 10.1186/s13148-021-01002-y.
Cabezón M, Malinverni R, Bargay J, Xicoy B, Marcé S, Garrido A, Tormo M, Arenillas L, Coll R, Borras J, Jiménez MJ, Hoyos M, Valcárcel D, Escoda L, Vall-Llovera F, García A, Font LL, Rámila E, Buschbeck M, Zamora L; CETLAM group .
Grupo cooperativo coautor: GESMD .
• Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Ann Hematol. 2021 Aug;100(8):1995-2004. doi: 10.1007/s00277-020-04360-4.
Janusz K, Izquierdo MM, Cadenas FL, Ramos F, Sánchez JMH, Lumbreras E, Robledo C, Del Real JS, Caballero JC, Collado R, Bernal T, Pedro C, Insunza A, de Paz R, Xicoy B, Salido E, García JS, Mínguez SS, García CM, Muñoz AMS, Barba MS, Rivas JMH, Abáigar M, Campelo MD .
Grupo cooperativo coautor: GESMD .
• Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features.
Blood Adv. 2020 Oct 27;4(20):5285-96. doi: 10.1182/bloodadvances.2020002206.
71